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ABSTRACT

Mahdi, Alaa. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2020. Identification of New Metabolic Mutations in the Fission Yeast
Schizosaccharomyces pombe that Sensitize the Cell to Hydroxyurea.

Cancer is a life-threatening illness and innovative research is therefore required to fuel
the development of new anti-cancer therapies. As an anti-proliferative drug, hydroxyurea
(HU) has been used in the treatment of various neoplastic and non-neoplastic diseases
such as sickle cell anemia, psoriasis, and viral infections. HU is a well-known inhibitor of
ribonucleotide reductase (RNR), an enzyme that generates dNTPs for DNA replication
and repair. In our genetic screen in fission yeast looking for mutants with defects in
checkpoint response, we also found a set of mutants that are highly sensitive to HU but
with a functional checkpoint response. It is likely that in addition to the RNR
suppression, HU induces cell lethality by a previously less understood mechanism
involving perturbations of various metabolic pathways. This study is to identify new
metabolic genes whose mutations sensitize the cells to HU in order to better understand
the cell-killing mechanisms of HU. We have identified new mutation in erg12 gene,
which encodes the mevalonate kinase enzyme in the ergosterol biosynthesis pathways.
While characterizing the erg12 mutant, we have unexpectedly found five multi-copy
suppressors including mns1, uge1, chs1, mug109 and hba1. Results from this study may
iii

help to better understand the cell-killing mechanisms of HU, the side effects, and drug
resistance associated with the HU-based chemotherapies. They may also promote
therapeutic innovations for the benefits of patients with cancer or fungal infections.
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INTRODUCTION
The DNA replication checkpoint
There are two DNA structural checkpoint signaling pathways operating in the fission
yeast Schizosaccharomyces pombe. The first is the DNA replication checkpoint (DRC)
which is activated in the presence of arrested replication forks during S-phase [4,26]. The
other is the DNA damage checkpoint (DDC) which is activated during G1 or G2 phase
when DNA is damaged [4,26]. The DRC is a surveillance signaling pathway activated to
prevent the genomic instability in response to replication stress. Under stressful
conditions, errors may happen while replicating DNA, which affects the genome integrity
and causes mutations. The activated DRC also protects the perturbed forks against
collapse. Several factors could perturb the DNA replication such as nucleotide depletion,
damage on the DNA templates, and polymerase inhibitors [4,10,27]. Activated DRC
stimulating the cellular signaling to promote cell survival and prevent mutations. In our
lab, HU has been used as an agent that activates the DRC and we look for mutants in
fission yeast with a dysfunctional DRC. Since the DRC is highly conserved in all
eukaryotes, the new checkpoint mechanism discovered in fission yeast is likely conserved
in higher eukaryotes including humans. During the screening of these dysfunctional DRC
mutants (chk mutants), we unexpectedly screened a group of non-checkpoint mutants
because the cell lethality is not caused by replication stress induced by HU.
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The checkpoint signaling pathways
The DRC signaling pathway is started by the sensor kinase Rad3 (ATR ataxia
telangiectasia homolog) with its regulatory subunit Rad26 (human ATRIP). Rad3 begins
the DRC signaling followed by recruitment of other downstream proteins to the stalled
replication forks. Rad3-Rad26 complex interacts with RPA-coated single-stranded DNA
(ssDNA) generated at the perturbed forks. Another complex called 9-1-1 (Rad9-Rad1Hus1) is also loaded onto the perturbed forks with the help of Rad17 and the replication
factor C complex RFC2-4, followed by transducer proteins and effectors (Figure 1)
[4,10,26]. These checkpoint proteins assembled at the perturbed forks to properly amplify
the checkpoint signal, targeting various downstream proteins responsible for stimulating
the cellular responses under replication stress. Although these activation mechanisms of
the checkpoint kinases have been well characterized in mammalian and yeast cells, how
they exactly become activated under replication stress remains controversial. Cells
lacking a functional DRC treated by HU, the DDC pathway is activated, suggesting the
unprotected forks collapse leading to broken forks that activates the DDC to suppress cell
division and stimulate DNA repair [26,27,34]. Studies in mammalian cell lines observed
the resistance to HU treatment by up-regulating RNR small subunit (Suc22 in yeast). In
yeast, the up regulation of Suc22 also suppresses the HU sensitivity of wild type and
DRC mutant cells, suggesting that RNR is the primary cellular target of HU [27].
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Figure 1: The DRC signal transduction pathway.
When the forks are perturbed during the S phase, the sensor kinase Rad3/Rad26 (ATR/ATRIP in
mammalian cells) initiates the signaling cascade by interacting with RPA protein attached to the
ssDNA. The 9-1-1 complex consisting of Rad1, Rad9 and Hus1 is also loaded with the help of a
clamp holder Rad17 and Rfc2-4. Rad3 is then activated by the mediator proteins Mrc1 (Claspin in
human cells) which induces the downstream phosphorylation of the effector kinase protein of the
DRC, Cds1 (CHK2 in human cells). In the presence of collapsed or broken forks, Rad3 activated
by the other mediator Crb2 (TP53BP1 in human cells) which facilitates the phosphorylation of
Chk1, the effector kinase for the DDC. HU treatment arrests DNA replication in proliferating
cells and activates the DNA replication checkpoint response
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The Checkpoint (chk) and the metabolic (non-chk) mutants
Methyl methane sulfonate (MMS) is one of the DNA alkylating agents, a major class of
anti-cancer drugs. MMS alters the bases in the DNA template by methylation which
blocks the polymerase movement during DNA replication [27]. Therefore, it is used in
this study to differentiate between the checkpoint (chk) and the metabolic (non-chk)
mutants. The chk mutants have mutations in genes involved in the DRC signaling
pathway and they are highly sensitive to the replication stress induced by hydroxyurea
(HU) as well as the DNA damaging agents such as MMS and UV [26,27,34].
Furthermore, HU arrests the chk mutants in S-phase and the chk mutants can be
suppressed by overexpressing Suc22, the small subunit of RNR and the primary target of
HU. On the other hand, the non-chk mutants have mutations in metabolic genes. These
mutants are highly sensitive to chronic HU treatment but are resistant to MMS and UV.
In addition, they cannot be rescued by Suc22 overexpression as the cell lethality is not
caused by replication stress but by the less-understood cell-killing mechanisms of HU.
Consistent with the new cell-killing mechanisms, HU arrests the non-chk mutants in
G2/M, not the S-phase of the cell cycle [26,27,34]. Examples of these metabolic mutants
that have been identified previously in our lab are erg11, hem13, ccr1, hcs1, mvd1, erg7,
and erg25 [26,27,34].
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Hydroxyurea (HU)
The therapeutic effects of HU and its primary cellular target RNR
HU has been used as an antimetabolite drug as well as for the management of sickle cell
anemia (SCA). The chemical structure of this agent is shown in Figure 2. HU attracts the
scientific interest due to its multiple clinical applications. The mechanism for HU’s
therapeutic effect cannot exactly be explained, but it is generally believed to be as an
inhibitor of ribonucleotide diphosphate reductase (RNR) (Figure 3) which is absolutely
needed in converting the ribonucleoside diphosphates to deoxyribonucleoside
diphosphates (dNDP) [7,17,26]. Indeed, HU treatment arrests the proliferating cells in S
phase. The small subunit of RNR containing a metal center, producing a tyrosyl free
radical. HU decreases the cellular dNTP levels by specifically quenching the tyrosyl free
radical and thus slow the replication forks [7,27]. In response to the slowed fork, the
DRC becomes activated to stimulate the RNR enzyme, increasing the dNTP production
to promote fork progress and preventing the forks against collapsing. In addition, the
activated DRC delays mitosis so the cell can properly finish the DNA replication after the
HU effect is removed [7,26,27]. Since the cell-killing mechanism of HU remains poorly
understood, studies suggested that HU might have an unknown secondary target inside
cells besides the RNR. Identification of such targets may improve the HU-based
chemotherapies or expanding the pharmacological applications of this drug for other
diseases.
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Figure 2. Structure of HU, monohydroxyl-substituted urea.

Figure 3: Structure of ribonucleotide reductase
Ribonucleotide reductase enzyme (RNR) consists a larger subunit R1 and a smaller subunit R2
(Suc22 in fission yeast ) required for the synthesis of deoxyribonucleotides (dNTPs) by
catalyzing the reduction of NDPs. The activated DRC inhibits cell devision by upregulates RNR
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to promote the dNTP production. Therefore, the HU sensitivity of the DRC mutants has been
reported to be suppressed by overexpression of Suc22 [26,27].

Secondary target(s) of HU
Recent studies suggested that in addition to RNR, HU may induce cell lethality by
targeting other cellular targets. Although the DRC defects in chk mutants sensitize the
cell to HU, hus mutants have been identified that carry a functional DRC. The cell death
in these non-chk mutants was due to cytokinesis arrest or oxidative stress in the presence
of mutations in heme or sterol biosynthesis pathways [26,27]. Screening for such mutants
provides an insight to the novel cell-killing mechanisms of HU. These hus mutants are
therefore classified as metabolic mutants or ‘non-chk’ mutants. In our lab, seven non-chk
mutations of various metabolic pathways have been identified previously, including
erg11, erg7, erg25 in ergosterol biosynthesis pathway, mvd1 and hcs1 in mevalonate
pathway, and hem13 and ccr1 in heme biosynthesis pathway [26,27]. The mechanisms
behind the cytotoxic effect of HU in these non-chk mutants are due to cytokinesis arrest,
oxidative stress or other uncharacterized mechanisms but not due to the RNR inhibition,
which induces S-phase arrest and DRC activation [26,27,34]. Screening and
characterization more metabolic mutants may thus help to identify the secondary cellular
target of HU and to better understand the cell-killing mechanisms of this clinically
important drug. Here, I report our identification and characterization of a metabolic
mutant erg12-1 in the mevalonate biosynthesis pathway.
7

The cytokinesis arrest in HU-treated erg11-1 mutant
Previous screening for new HU sensitive mutants in our lab has identified a novel
mutation in erg11 involved in ergosterol biosynthesis [26,34]. The gene product of erg11
is the enzyme sterol-14a-demethylase (Cyp51in humans), which is highly conserved in
all eukaryotes (Figure 4). Interestingly, Erg11 is known to be the major therapeutic target
of antifungal agents used in the clinics such as clotrimazole and terbinafine. Further
analysis has been done in this mutant in order to understand the mechanism by which this
mutation induces HU sensitivity. It has been noticed that HU at low doses stably arrests
erg11-1 mutant cells in cytokinesis, which is the cytoplasmic division of the cell before
separating into two daughter cells. erg-11 mutant cells appear to have a sterol deficiency
as determined by fluorescent microscopy. The mutant enzyme may also produce a toxic
byproduct, leading to HU sensitivity. To investigate this possibility, exogenous ergosterol
was added to the erg11-1 mutant to test whether the mutant can be rescued chemically.
However, the results showed that the erg11-1 could not be rescued by exogenous
ergosterol as the cell lacks the transporter that prevents the use exogenous sterol. Another
test was to examine the effect of Erg11 inhibitors clotrimazole and terbinafine on the
erg11-1 mutant. While the checkpoint mutants, including rad3, cds1, and chk1 showed a
similar resistance as in wild type cells, the erg11-1 cells were much more sensitive to the
inhibitors. All together, these results showed that the sterol deficiency is likely the reason
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for the observed cytokinesis arrest and HU sensitivity [26,34]. Furthermore, various drug
combinations of HU with the Erg11 inhibitors (antifungal azoles) have synergistic cellkilling effects on fission yeast as well as the fungal pathogen C. albican [26,34]. Beside
the erg11-1 mutation, mutations in erg7 and erg25 in the ergosterol pathway have also
been found in our lab although not further characterized yet.

The oxidative stress induced by HU in hem13-1 mutant
In our lab, another novel mutation T263D in hem13 gene has also been identified. This
gene is predicted to encode coproporphyrinogen III oxidase enzyme in heme biosynthesis
that is homologous to coproporphyrinogen oxidase (CPOX in humans) [27]. HU
treatment in this mutant generates a significant oxidative stress. Consistent with this
mechanism, flow cytometry analysis of the hem13-1 mutant cells showed that HU
arrested the cells at G2/M phase, not the S phase. Thus, the HU-induced cell death in this
mutant is by the accumulated ROS inside the cells. Further experimental evidence is that
treatment with the antioxidant N-acetylcysteine (NAC) promotes cell survival in HU and
exogenous hemin completely rescues the mutant. Interestingly, pretreatment of wild type
cells with sampangine, the inhibitor of hem13 significantly enhanced the cell-killing
effects of HU [27].
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Use of the fission yeast Schizosaccharomyces pombe as a model organism
The fission yeast S. pombe is a rod-shaped unicellular eukaryote that contains only three
chromosomes [11]. It divides by medial fission and grows by tip elongation. Most of the
cellular processes are conserved in S. pombe, making it an excellent laboratory organism
for studying the cellular and molecular mechanisms that are conserved in higher
eukaryotes, including humans. S. pombe also offers several technical advantages in this
study: it has a rapid life cycle between 2 to 4 hours at 36 ̊C–25 C
̊ . It is easy to handle and
to isolate mutants for studying a particular process of interest in either haploid or diploid
cells [11]. The specific metabolic pathways that have been studied for this thesis using
this model are described below.

Ergosterol biosynthetic pathway
Ergosterol (cholesterol in mammalian cell membranes) is an integral component of the
fungal cell membrane. It is vital for cell growth and development since it is involved in
the coordination of many other pathways that maintain the fluidity, stability and integrity
of the cell [1,2,3]. Due to its importance, the ergosterol biosynthesis pathway has been
studied intensely as a target of antifungal drugs like "azole" class [6,23,25]. It is also
considered as vitamin D2 precursor and used in steroid hormone drugs. The perturbations
of ergosterol synthesis could cause deficiency of sterol which alters the membrane
functions as well as mitochondrial activities [25]. The biosynthesis of ergosterol (Figure
10

4) is a complex process and involves enzymes that can be separated in three major parts:
mevalonate, farnesyl pyrophosphate (farnesyl-PP) and ergosterol biosynthesis [3,13].
Mevalonate pathway is started by the synthesis of HMG-CoA by the enzyme ERG13.
Following the synthesis of HMG-CoA, farnesyl pyrophosphate (farnesyl-PP) is
synthesized by the enzymes ERG12, ERG8, ERG19, IDI and ERG20, which are essential
enzymes for cell growth. The last part mainly occurs in the endoplasmic reticulum (ER),
done by 15 steps, converting the farnesyl-PP to squalene follow by the biosynthesis of
lanosterol and then ergosterol. Inhibiting the HMG-CoA reductase in the mevalonate
pathway by statins affects the production of all intermediate molecules that are needed
for ergosterol as well as for other biosynthetic pathways like ubiquinone, dolichol, and
isoprenoids (Figure 4), which likely lead to various side-effects associated with statins
[3,13]. Therefore, developing a drug targeting specifically the downstream enzymes of
the sterol biosynthesis pathway might be more beneficial to the patients with less sideeffects.
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Somanon Bhattacharya et al. mBio 2018; doi:10.1128/mBio.01291-18

Figure 4: Ergosterol biosynthetic pathway.
Different parts of the ergosterol biosynthetic pathway are shown including the names of the
enzymes and their inhibitors (red text). Boxed enzymes are nonessential for cell growth [3].
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Multi copy suppressors
Overexpression of a suppressor gene can make the cell able to bypass a gene mutation
leading to rescuing the mutant phenotype. The suppression interactions tend to happen in
genes that have a related functional pathway. Therefore, screening for the suppressors has
been used extensively to identify genes that are involved in the related pathways, which
may guide to the discovery of new therapeutic opportunities [27]. In this study, five genes
have been found whose upregulation can suppress the mutations in ergosterol pathway.
Three of them are genes involved in cell wall formation including mns1, uge1, and chs1.
The other two suppressors are classified as Ras superfamily genes (see below).

Ras superfamily
The Ras superfamily is a group of small GTP-binding proteins that are categorized in six
subfamilies (Fig 5A) [19]. Ras superfamily proteins are involved in many cellular
functions associated with the regulation of cell growth and cell survival like signal
transduction pathways and mevalonate pathway [19,24]. A previous study has shown that
a mutation in Ras protein are associated with the up to 30% of all human cancers [19].
Ras proteins can undergo by farnesylation or geranylgeranylation (Fig 5B) which
controls several cellular processes involving in the cell proliferation and vesicle
trafficking. Furthermore, many members of the Ras protein superfamily are
polyprenylated leading to hydrophobic modifications which further control the cell
13

membrane. Hence, they are linked to the prenylation correlated diseases [8,19,24].
Combination therapy of prenylation inhibitors with the standard therapy may enhance the
treatment of some incurable and devastating diseases. They are considered as an
intermediate component in the mevalonate pathway [19]. During the screening of the
mutations that sensitizes the cell to HU, two of the Ras family genes, mug109 encoding
Rab GTPase binding protein and hba1 encoding Ran GTPase binding protein have been
identified. Upregulation of these two particular genes may therefore improve the survival
in HU of a mutant cells with defect in sterol biosynthesis.

A

B
W. Likus et al. / Drug Resistance Updates 25 (2016) 13–25

Figure 5: Ras superfamily
A. The 6 subfamilies of Ras-superfamily. B. The mevalonate pathway with a series of
intermediate steps leading to various products. The synthesis of farnesylpyrophosphate (FPP)
pathway is further divided into a number of branches including the biosynthesis of cholesterol,
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ubiquinone, heme A and dolichols. Ras proteins can be either farnesylated or geranylgeranylated
by the protein prenylation process [19].

Yeast cell wall
The fungi’s cell wall is the most significant structural difference from mammalian cells.
The integrity of fungal cell wall depends on cell wall polysaccharides. Some of these
polysaccharides are present only in fungi and are therefore considered as excellent targets
for antifungal chemotherapies. The main components of the fungal cell wall
polysaccharides are 𝛽-1,3 glucan, 𝛽-1,6 glucan, and various glycoproteins/
mannoproteins (Fig.6), which are essential for the maintenance of intracellular osmotic
pressure and for the integrity of the cell wall [1,14,18]. The chemical structure and the
biosynthesis of the fungal cell wall components have been studied extensively due to
their significant roles in various pathways like the regulation of MAPK signaling
pathways [1,14,18]. The MAPK signaling pathways are activated when the cell wall is
damaged to activate the repair processes of the cell wall. During the screening of the
mutation that sensitizes the fission yeast to HU, I have found the cell wall enzymes
including Mannosyl-oligosaccharide 1,2 𝛼 -mannosidase (mns1), UDP-glucose 4epimerase (uge1), and Chitin Synthase (chs1). These particular enzymes may therefore
function in the regulation of the ergosterol biosynthesis pathway for maintaining the cell
wall integrity.
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Figure 6: Yeast cell wall structure
First, β-1,3-glucan is synthesized from UDP-glucose (UDP-Glc) by β-1,3-glucan synthase, then
β-1,6-glucan is added to the β-1,3-glucan followed by addition of mannoprotein to make
polysaccharide mannoprotein complex. Finally, chitin is synthesized from UDP-Nacetylglucosamine (UDP-GlcNAc) by chitin synthase and connected to β-1,6-glucan. The lightercolored circles are undefined polysaccharide chains [5].

Mannosyl-oligosaccharide 1,2-alpha-mannosidase (Mns1)
Mns1 is involved in glycoprotein catabolic process, particularly in the protein
glycosylation pathway [5,14,30]. It is located in the membrane of endoplasmic reticulum
membrane and Golgi, removing one mannose residue from the glycosylated protein
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which is essential for early N-glycan processing. Therefore, α-mannosidase is considered
as ER-associated protein degradation (ERAD); responsible for trimming
Man9GlcNAc2 N-glycans in the endoplasmic reticulum to form Man8GlcNAc2 isomer B
which is the substrate for oligosaccharide elongation [5,14,30]. It is believed that the
degradation role of ER mannosidase is independent on its enzymatic activity. The human
homologue of Mns1 is MAN1B1whose mutations are associated with mental retardation
diseases. A previous study has shown that disruption of the mns1 gene cause defects in
the degradation of certain misfolded glycoproteins [30]. Selective inhibitor of αmannosidase enzyme could block the abnormal oligosaccharides formation, leading to
reduction of metastasis and tumor growth [16,30]. Kifunensine is a well-known αmannosidase enzyme Inhibitor. Targeting this enzyme may also help in designing novel
therapeutic agents that prevent the degradation of misfolded proteins in some genetic
diseases that are characterized by rapid degradation of misfolded glycoproteins [30].

UDP-glucose 4-epimerase (Uge1)
S. pombe glycoproteins contain a large amount of galactose and mannose. Uge1 is the
key enzyme involved in the galactose synthesis (Leloir pathway) (Figure 7) in cytosol
[28,32]. It converts β-D-galactose to glucose-1-phosphate and the predominant enzyme
involved in galactosylation of glycoproteins in S. pombe. The human homologue of Uge1
is called GALE whose mutations are associated with galactosemia [28,32]. A previous
17

study has shown that uge1 deletion strain exhibits a severe defect in galactosylation [6].
A deletion library screens study has been done for screening the sensitivity of antifungal
drugs showed that uge1 deletion sensitizes the yeast cells to Micafungin, an antifungal
drug that inhibits (1,3)-β-D-glucan synthases [6].

Figure 7: Leloir pathway of galactose metabolism
Galactose is phosphorylated by galactokinase to form galactose-1-phosphate, which is then
transformed to glucose-1-P by uridylyltransferase. UDP-galactose can also be formed from UDPglucose via the UDP galactose-4’-epimerase Uge1 (GALE in humans) reaction.

Chitin synthase (Chs1)
Chs1 has the glycosyltransferase activity, an enzyme that is responsible for converting
the UDP-N-acetylglucosamin (UDP-GlcNAc) to chitin [18,21]. Chitin, which is
18

composed of 𝛽-(1,4) N-acetyl-D-glucosamine (GlcNAc), will then be connected to 𝛽1,3-glucan and 𝛽-1,6-glucan for building larger polysaccharide complexes in the cell wall
synthesis. The major function of Chs1 is for the formation of primary septum during
cytokinesis as well as a vital role in cell separation after cytokinesis. The synthesis of the
spore cell wall in S. pombe requires Chs1 and previous studies have shown that the ∆chs1
strain forms abnormal asci [21,33,15]. Different from human cells, chitin is considered as
a unique fungi’s cell wall polysaccharide. The uniqueness of this enzyme makes it an
ideal target for antifungal drugs like Nikkomycin [18].
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SPECIFIC AIMS
1. Genetic screening to identify the mutated genes in the non-chk mutant M9 that is
sensitive to HU.
2. Identification of the mutation in M9.
3. Identification of multi copy-suppressor genes of the identified mutations in the
ergosterol pathway.
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SIGNIFICANCE
HU inhibits RNR, which slows down the DNA replication process and activates the DRC
to upregulate RNR and promote DNA synthesis. However, dysfunctional DRC is not the
only way that lead to the cell death in the presence of HU. Recent studies have shown
that HU induces cytokinesis arrest or oxidative stress in non-chk mutants of various
metabolic pathways [25,26,27].
In this study, we have used genetic methods in the fission yeast S. pombe to screen for a
metabolic mutation that sensitizes the cells to HU. The identified mutation in the
ergosterol pathway and its multiple copy suppressors gene screened during this study
may help to improve the HU-based chemotherapies or expand the therapeutic spectrum of
HU.
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MATERIALS AND METHODS
Yeast strains, plasmids and chemical compounds
All yeast strains were grown in YE6S media (0.5% yeast extract, 3% glucose, and the 6
supplements of adenine, uracil, histidine, lysine, leucine, and arginine) or in the EMM6S
media (lacking one of the appropriate supplements) at 30˚C. The mutagen methyl
nitrosoguanidine (MNNG) was used to generate random mutations in the genome of a
wild type S. pombe strain. HU was purchased from Sigma and dissolved in distilled water
as a 1.0 M stock solution. Phloxin B dye was used as an indicator of cell lethality. All
yeast strains used in this study are listed in Table 1, whereas the PCR primers and the
plasmids are listed in Table 2 and Table 3, respectively. The plasmids and mutations were
confirmed by DNA sequencing (Retrogen, San Diego, CA).
Drug sensitivity test
The drug sensitivity of the screened mutants was measured by the spot assay. The strains
grown overnight in an appropriate medium. 1 OD/ml cells (1 OD = 2x107 yeast cells of
logarithmically growing fission yeast culture) was diluted in 3-fold or 6-fold steps. Three
μl of the serial dilution cells was spotted onto YE6S plates as a control plate or YE6S
plates containing different concentration of HU (2.5 mM or 5 mM). Wild type cells were
used as negative control while the HU-sensitive Δrad3 cells as positive controls. The
plates were incubated at 30˚C for 2-3 days and then photographed.
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The collection of metabolic (non- chk) mutants.
A collection of the metabolic mutants by genetic screening that are sensitive to HU but
resistant to the DNA damaging agent MMS was provided by Rittu Samuel, a former MS
graduate student in our lab. This genetic screening was started by crossing the new set of
the metabolic mutants with the known mutants in our lab (erg11, ccr1, and hcs1) to

eliminate known mutations. These mutants were then backcrossed with the parental
strains three times to remove the by-stander mutations followed by intercrossing
(crossing these mutants with each other) to identify the complementation groups, in
which two mutants of opposite mating type were spotted on top of each other to
determine if they are allelic or not. The HU resistant spots suggest that the two mutants
have mutations in different genes and are non-allelic. Sensitive spots indicate that the
mutants being crossed likely have mutations in the same genes or allelic. Finally, nine
complementation groups were identified by Rittu Samuel, suggesting nine potential
metabolic genes involved. Currently, three of these potential metabolic genes has been
identified (erg7, erg25 previously and erg 12 in this study). Therefore, five more
unknown metabolic genes remain to be identified.
•

Group 1: M7, U1, YX347, YX406, YX433

•

Group 2: M9, M12

•

Group 3: U5, SN79, YX35, YX86, YX102, YX147, YX482, YX503

•

Group 4: M38, YX175

•

Group 5: YX71, YX171, YX397, YX517
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•

Group 6: YX146, YX210

•

Group 7: YX348, YX499

•

Group 8: SN31

•

Group 9: YX180

Identification of the mutated gene(s) in M9 mutant
M9 mutant from group 2 was selected randomly for transformation with a genomic
library marked with ura4 by electroporation. The colonies grown on EMM plates lacking
uracil were tested the HU sensitivity. The HU resistant colonies were selected to recover
the plasmids that confer HU resistance to M9. The recovered plasmid DNAs were
digested with the restriction enzymes EcoRI, EcoRV and HindIII followed by analysis in
agarose gel electrophoresis. The bands obtained were compared with that of the empty
vector and then classified into different subgroups. From each subgroup, a representative
plasmid was selected to be transformed back into the M9 mutant to confirm the conferred
HU resistance. The plasmids that showed HU resistance partially or completely after
retransformation were then sequenced to identify the genes that confer M9 with HU
resistance. The sequencing result was analyzed and aligned using MacVector software.
(Figure 8)
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Identification of the mutations in erg12
The genomic DNA from the M9 mutant was purified. Based on the sequences of the
identified genes, cloning primers were designed that amplified a 2988 bp PCR product of
erg12. The conditions used for Phusion PCR amplification was 98ºC denaturation
temperature, 50ºC annealing temperature and 72ºC as extension temperature for 1
minutes and 30 seconds (30 cycles) using a Thermal Cycler. The PCR product was
analyzed by agarose electrophoresis. Band was cut out for purification of the PCR
product. The purified PCR product was sequenced using the primers specifically
designed for sequencing erg12 in order to identify the mutations in this particular gene.

Screening for multiple-copy suppressors of erg12 mutant
The erg12 mutant was transformed with genomic DNA libraries that carry the ura4
marker. The transformed mutant cells were plated on media lacking uracil followed by
replica plating on HU plates to screen for HU resistance colonies. The recovered
plasmids for the HU-resistant yeast colonies were sent out for DNA sequencing and
identification of the suppressor genes. The suppressor genes showing in sequence results
have been cloned and retransform to the erg12 mutant strain and retest the HU
sensitivity. The yeast transformation was performed using the lithium acetate method.
Cells were grown up overnight then harvested by centrifugation. Pellets were washed
with sterile water 3 times then resuspend in 100 mM lithium acetate (pH 4.9). 1l of
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plasmid DNAs were added to 100 µl cells and then mixed with 290 l of 50% PEG3350
in 100 mM lithium acetate (pH 4.9). The cells were incubated for 1 h at room temperature
and then heat-shocked for 30 min at 42 ˚C. After recovering in the rich YE6S media at
30˚C for 1 h, the cells were spread onto plates lacking uracil for colony formation.
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Table 1: List of S. pombe strains used in the study
Strain
TK7

Genotype
h- leu1-32 ura4-D18 ade6-M210

Source
Xu Lab

TK48

h+ leu1-32 ade6-M210

Xu Lab

NR1826

h- ∆rad3::ura4 leu1-32 ura4-D18 ade6-M210

P. Russell Lab

YJ1298

h+ erg11(G189D):kanR leu1-32 ura4-D18 ade-M216

Xu Lab

YJ1299

h- erg11(G189D):kanR leu1-32 ura4-D18 ade-M210

Xu Lab
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Table 2: List of PCR and sequencing primers used in the study
Name
SpErg12(T)SphI-f
SpErg12(P)SacI-b
SpErg12(450-469)f
SpErg12(886-905)f
SpErg12(561-580)b
SpMns1(P)PstI-f
SpMns1(T)BamHI-b
SpMns1(529-507)b
SpMns1(409-432)f
SpMns1(1031-1052)f
SpUge1(P)SphI-f
SpUge1(T)XmaI-b
SpUge1(639-618)b
SpUge1(441-460)f
SpUge1(822-842)f
spChs1(P)SphI-f
spChs1(T)SacI-b
SpChs1(454-75)f
SpChs1(540-20)r
SpChs1(1017-36)f
SpChs1(1545-66)f
SpChs1(2137-56)f
SpMug109(P)PstI-f
SpMug109(T)SacI-b
SpMug109(356-339) b
SpMug109(237-256) f
SpHba1(P)SphI-f
SpHba1(T)SacI-b
SpHba1(586-605) b
SpHba1(431-454) f
SpHba1(832-851)f
pIRTf
ura4-prom-b2

Sequence (5’ -> 3’)
atacgCAtgcagtaacgttgtcc
tgcaGAGctccttcaaaaaggagc
TTGGCAGCATGTAACAGTGG
CATCAGAGTGCCATGAAAGA
GGGTACAAAGCATTGCTGAG
aggtCTgcagccttattcttctacc
gtccggAtcctaatacaataaatcaag
CATTTGATCTAGGTAAGCCCGTG
GGAGGACTCCTTTCTTCTTATCAC
CTTCATTAGAAGCAGCACGTAC
tcggGCatgcttgtttaccagcagg
atgtCCCgggtattaagtgtagtttg
CCATACACGGTAGCAGATGAAG
CAGCTTTGGACAAGGTCTTC
GTGAACTCGGTGAAGATCCTC
aataGCAtgcggtgatatttaaaatgag
cttaGagctccatatacaacggcatg
GAGCGAGAATTTGCTTACATGC
GGGCTGCCTTAAAGTGAATAG
TTTAGATGCTGGAACACGTC
TGCTATCTGTCACTACTACAGG
TGCAACACACATGACGTTTC
5’ttacCTGcagccctaaaagcgtatac
5’aaatGAGctcaatcctgaacttctgg
ACACCAGGGATGGAATAC
CCCATTTGCTTTGTTAGCTC
5’ttgtGCAtgcgctcgagctatcgattag
5’taagGAGctcttgaataaaattatatttg
TCTGTTTCAACTGCTGTTCC
CTTCATTCTCTAATGCCTCGTCTC
ATATTCAGTGTTCGCGCAAG
CTTAGGGATTCTATGCAAAACC
CCTATTTAGAGAAAGAATGCTGAG
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Note
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Gene Cloning
Gene Cloning
Sequencing
Sequencing
Sequencing
Sequencing
Sequencing

Table 3: List of plasmids used in the study
Name
pAPS42
pAPS43
pIRT-2U

Description
Prom+Erg12+term(ura4+)
Prom+Erg12+term(ura4+)Hus169
ura4+ vector
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Source
Xu Lab
Xu Lab
Xu Lab

RESULTS
Identification of new metabolic mutants
In order to identify new DNA replication checkpoint (DRC) mutants, we have carried out
an extensive genetic hus (HU sensitive) screening in the fission yeast S. pombe looking
for mutants that are sensitive to HU. This screen unexpectedly screened a new group of
metabolic mutants whose cell death is not caused by the replication stress induced by
HU, but by the less understood mechanisms involving metabolic mutations, oxidative
stress and cytokinesis arrest. These hus mutants were classified as non-chk mutants
because unlike the chk mutants, the non-chk mutants are not sensitive to the DNA
damaging agent MMS. To reconfirm their non-chk or metabolic mutations, Suc22, the
RNR small subunit and the major regulation target of the DRC, was overexpressed in
these mutants. The results showed that these non-chk mutants were not rescued,
consistent with their mutations in metabolic pathways, not the DRC pathway. The nonchk M9 mutant that belongs the complementation group 2 was selected randomly for this
study. To identify the mutation(s) in M9, S. pombe genomic expression libraries made
from the wild type strain TK7 were transformed into the mutant (Figure 8). The
expression vector used in this library was pIRT-2U, which has ura4 gene as a selective
marker. After the transformation by electroporation, the mutant cells were spread onto
EMM6S medium plates lacking uracil. The yeast colonies formed on the plate were
replicated onto YE6S plates containing 5 mM HU to screen for HU-resistant colonies.
After collecting a total of ~30 HU resistant colonies, their HU resistance was examined
by spot assay analysis (Figure 9). Once the HU resistance was confirmed, the plasmids
were recovered from the yeast colonies. These recovered plasmids were amplified and
then purified from E. coli followed by digestion with restriction enzymes EcoRI, EcoRV
and HindIII (Figure 10). After agarose gel electrophoresis of the digested plasmids, the
pattern of the bands of each recovered plasmid were examined and compared with those
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obtained from the empty vector pIRT-2U digested with the same restriction enzymes. As
a result, 16 different sub-groups of the recovered plasmids (Figure 10) were determined
for this mutant. A representative of each group of recovered plasmids was then
retransformed back into the M9 mutant. The HU sensitivity of the transformed mutants
was assessed again by spot assay using the mutant itself and wild type cells as the
controls (Figure 11). 10 plasmids rescued the M9 mutant and therefore the HU resistance
conferred by those plasmids were reconfirmed by a more accurate 6 spot assay (Figure
12). These plasmids were then sequenced using primers on both sides of the gene cloning
site of pIRT-2U in order to identify the genes that are cloned in the vectors and
responsible for conferring the HU resistance in M9.

Identification of the mutated gene in M9.
PomBase is the database containing all genomic DNA sequence information of S. pombe.
It was used as the reference to locate the genes on a particular fragment that is cloned in
pIRT-2U in the genomic DNA expression library. The sequences obtained from the
sequencing from either the 5’ or 3’ end using the primers pIRT-f and ura4-prom-b2. For
the plasmids that rescues M9, alignment of the genomic DNA carried in plasmid #9 or P9
showed that it contains the expression cassettes of three genes. One is erg12 gene
encoding the mevalonate kinase enzyme of the ergosterol biosynthetic pathway. The
second is chs1 encoding the chitin synthase, and the third is aps1 gene that encodes
diadenosine 5',5'''-p1, p6-hexaphosphate hydrolase. This result suggests that erg12, chs1
and aps1 are the candidate genes whose mutations may sensitize the M9 cells to HU
(Figure 13A). Sequence alignment of the DNA fragment from P8 showed that it
contained two candidate genes that might be mutated in M9, uge1 gene encode UDPglucose 4-epimerase and hba1 whose gene product is Ran GTPase binding protein, one of
the Ras superfamily proteins (Figure 13B). Sequence alignment of the DNA from P16
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showed that it contained two candidate genes: mns1 encodes mannosyl-oligosaccharide
1,2-alpha-mannosidase and mug109 encoding Rab GTPase binding protein one of the Ras
superfamily proteins (Figure 13C).
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Figure 8: Flow chart for identification of the mutated genes in the newly screened
metabolic or non-chk mutants that are sensitive to HU.
After mutagenizing the wild type S. pombe cells, the HU sensitive mutants were selected. The
DNA damaging agetnt MMS was used to distinguish between the chk and non-chk mutants. The
non-chk mutants were classified into 9 complementation groups. A representative mutant from
each group was transformed with S. pombe genomic DNA expression libraries derived from the
wild type strain TK7. The transformed cells were grown up on plates lacking uracil to screen the
yeast colonies that became resistant to HU. Plasmids recovered from the yeast colonies were
transfected into ultra-competent DH5α bacterial cells and purified. These plasmids were digested
using restriction enzymes followed by agarose gel electrophoresis. Plasmids carrying different
digested pieces of DNA were categorized into sub-groups and a representative from each subgroup was retransformed into the mutant to confirm the HU resistance by the standard spot assay.
Plasmids capable to rescue the mutants or suppress the HU sensitivity of the mutants were
sequenced to identify the candidate genes.
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Figure 9: Spot Assay analysis of the HU sensitivity of the isolated M9 colonies after
the transformation with S. pombe genomic DNA library.
M9 mutant was transformed with genomic DNA library and the colonies with conferred
HU resistance were isolated. HU sensitivity of the isolated colonies was assessed by spot
assay analysis. Wild type and rad3 cells were used as the controls. A total of 30 colonies
were tested that are partially or fully rescued. Plasmids from the HU-resistant colonies
were recovered and purified from E coli for further analysis.
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Figure 10 : Restriction digestions of the recovered plasmids by EcoRI, EcoRV and
HindIII.
The digested plasmids were analyzed by an agarose gel electrophoresis. The band patterns
obtained were used to categorize the plasmids into sub-groups. 16 sup-groups are listed on the
right. The stars indicate that plasmids having the bands similar to those obtained from the vector
pIRT-2U digested with the same restriction enzymes.
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Figure 11: Spot assay analysis of the M9 HU resistance colonies after
retransformation.
16 recovered plasmids were transformed back into M9 mutant and HU sensitivity of the
transformed mutant carrying the indicated plasmids was assessed by spot assay. Wild
type and rad3 cells were used as the controls. All plasmids were sent for DNA
sequencing except plasmid 1, 4 and 14 that did not show any rescuing effect in M9.
Plasmid 5, 11, and 12 did not show good sequencing results. Therefore, only 10 plasmids
were selected for detailed 6 spot assay analysis (see below).
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Figure 12 : Spot assay analysis of the M9 resistance colonies after retransformation.
Spot assay analysis for the 10 plasmids with their corresponding genes responsible for
rescuing the M9 mutant. Plasmid 8, 9 and 16 were selected for further analysis. The
names of the genes and their encoded proteins or enzymes are listed below:
Msm1: mitochondrial methionine-tRNA ligase, Cdc1: DNA polymerase delta small
subunit, Pfl7: cell surface glycoprotein flocculin, Cox13: cytochrome c oxidase 13,
SPAC1B2.06: uncharacterized protein, SPAC17G6.03: extracellular 5'-nucleotidase
human NT5E family, Uge1: UDP-glucose 4-epimerase, Hba1: Ras superfamily, Ran
GTPase binding protein, Stm1: vacuolar amino acid transmembrane transporter, Csk1:
cyclin-dependent kinase activating kinase, Mns1: mannosyl-oligosaccharide 1,2-alphamannosidase, Mug109: Ras superfamily, Rab GTPase binding protein, Erg12:
mevalonate kinase, Chs1: chitin synthase, and Aps1: diadenosine 5',5'''-p1,p6hexaphosphate hydrolase.
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Figure 13: Identification of the genes that may render mutant M9 resistant to HU.
A) Plasmid 9 that rescued the M9 mutant carried three candidate genes erg12, chs1and aps1.
B) Plasmid 8 that rescued the M9 mutant carried two candidate genes uge1 and hba1.
C) Plasmid 16 that rescued the M9 mutant carried two genes mns1 and mug109.
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Identification of a missense mutation in erg12 gene
The sequencing and cloning primers were specifically designed for erg12 genes (Table
2). The genomic DNA was purified from the M9 mutants. The erg12 genes (2988 bp)
were amplified by PCR using the cloning primers and the high fidelity Phusion DNA
polymerase. The PCR product (Figure 14A) was analyzed by agarose electrophoreses, the
band was cut out for purification. The purified PCR product was sequenced using the
primers specifically designed for sequencing erg12 to identify the potential mutations in
this particular gene. Based on the sequences result of erg12, a single G-to-A mutation
that changed the alanine to threonine at amino acid position 142 (A142T). The sequence
reading done by using the MacVector and 4-Peak software (Figure 14B,14C). The
mutated amino acid is highly conserved from yeast to humans as shown in Figure 15
(A148T in human enzyme).

40

A

B

C

Figure 14: Identification of a missense mutation in erg12 that likely sensitizes M9 to
HU.
A) The PCR product of erg12 gene using SphI and SacI primers.
B) DNA sequencing of the erg12 PCR product identiﬁed a single G-to-A mutation that
causes A142T amino acid change in the enzyme using 4-Peak software
C) DNA sequencing of the erg12 identiﬁed a single G-to-A mutation that causes A142T
amino acid change in the enzyme using MacVector software
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A

Figure 15: The mutated amino acid residues in Erg12 is highly conserved in yeasts,
mouse and humans.
Regional amino acid sequences of Erg12 of S. pombe, S. cerevisiae, human, and mouse were
aligned together. The amino acids highlighted in blue box are the mutated Alanine (A) residues at
A142T (A148T in human).

Cloning of the erg12 gene
To confirm that M12 mutant is allelic to M9 or having a mutation also in erg12, erg12
was cloned (Figure 16) into an S. pombe expression vector. The plasmid was then
transformed to M9 as well as the M12 mutant. After transformation, the plates were
replicated onto plate containing 5 mM HU and then analyzed by spot assay (Figure 17).
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Figure 16 : Cloning of erg12 gene
Wild type and mutant erg12 gene were cloned on pIRT-2U expression vector by PCR with
primers containing the SphI and SacI sites. The resulting 2988 bp PCR products was purified by
agarose gel electrophoresis. The purified fragment and the expression vector were digested with
SphI and SacI enzymes and ligated into the pIRT-2U vector between the SphI and SacI sites. The
ligation mixture was transformed into 5DH𝛼 competent cells to make copies of recombinant
DNA plasmids. The transformed cells were spread on plates containing carbenicillin for 24h at
37℃ . The colonies resistant to the antibiotic were selected for colony PCR screening. The
plasmids were purified from the positive colonies and then digested with SphI and SacI to
visualize the bands of vector band and the erg12 expression cassettes that was cloned between
SphI and SacI.
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Figure 17: HU sensitivity of M9 and M12 transformed with vector expressing wild
type or mutant erg12 as determined by spot assay.
Expression of wild type and mutant erg12 from the vector fully rescued M9 and M12, which
shows that consistent with the complementation assay, both M9 and M12 mutants may have the
mutations in the same erg12 gene.
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Identification of the suppressor genes that may affect the mevalonate pathway
While identifying the mutations in M9, a few other plasmids also rescued the mutant M9,
suggesting those plasmids may carry suppressor genes. Plasmid 8 and plasmid 16 were
selected for further study. As described above, plasmid 8 contained two genes. uge1 gene
encodes UDP-glucose 4-epimerase and hba1 which is Ran GTPase binding protein
(Figure 13B). uge1 and hba1 genes were cloned using the method similar to that in erg12
cloning (Figure18). Plasmid16 contained two genes. The first is mns1 encoding
mannosyl-oligosaccharide 1,2-alpha-mannosidase and the second, mug109 encoding Rab
GTPase binding protein (Figure 13C). The cloning of mns1 and mug109 is shown in
Figure 19. Chitin synthase chs1 gene found in plasmid 9 (Figure 13A) was also cloned to
study its potential suppressor effect (Figure 20). In total, five candidate genes were
cloned for testing their suppressor functions. They were transformed into the mutant M9
then tested the HU sensitivity by spot assay (Figure 21). The results showed that while
overexpression of mns1, uge1, and mug109 can partially or fully rescuing erg12-1
mutant. I then transformed these plasmids into other ergosterol mutants screened in our
lab previously such as erg7-1 (M7) mutant and erg25-1 (M38) mutant (Figure 22) and
(Figure 23).
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Figure 18: Cloning of uge1 and hba1 genes into the expression vector pIRT-2U.
A) PCR cloning of uge1 gene into pIRT-2U expression vector between SphI and XmaI sites.
B) PCR cloning of hba1 gene into pIRT-2U expression vector between SphI and SacI sites.
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Figure 19: Cloning of mns1 and mug109 gene into the pIRT-2U expression vector.
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A) PCR cloning of mns1 gene into pIRT-2U expression vector between PstI and BamHI sites.
B) PCR cloning of mug109 gene into pIRT-2U expression vector between PstI and SacI sites.

Figure 20 : Cloning of the chs1 gene.
PCR cloning of chs1 gene into pIRT-2U between SphI and SacI sites.
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Figure 21: Identification of multicopy suppressors of erg12-1 mutant.
Expression of Mns1, Uge1, Mug109 and Hba1 can partially or fully suppress the HU sensitivity
of the erg12-1 (M9) mutant. In contrary, expression of Chs1 under similar conditions did not
rescue the M9 mutant. The wild-type and rad3∆ checkpoint mutant cells were used as a control.
Vec, empty vector. Three serial dilutions of the cultures of the indicated transformants were
spotted on YE6S plates or YE6S plates containing 2.5- or 5-mM HU. The plates were incubated
for 3 days at 30°C and then photographed.

Figure 22: The multi-copy suppressors of erg7-1 and erg25-1
Expression of Mns1, Uge1, and Chs1 can suppress the HU sensitivity of the ergosterol mutants
M38 and M7. Each gene was expressed on erg7-1 (M7) mutant (the left) and on erg25-1 (M38)
mutant (the right). The wild-type and rad3Δ checkpoint mutant were used as a control. Six serial
dilutions of the mentioned genes transformation were spotted on YE6S plates and YE6S plates
containing 2.5- or 5.0-mM HU. The plates were incubated for 3 days at 30°C and then
photographed.
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Figure 23: Overexpression of mug109 rescued M7, M9 and M38 mutants with
defects in the ergosterol biosynthesis.
mug109 was expressed on a vector in erg12-1 (M9) mutant, erg7-1 (M7) mutant, and erg25-1
(M38) mutant. The wild-type and rad3Δ checkpoint mutant were used as a control. Vec: empty
vector. Three serial dilutions of the mug109 transformed cells were spotted on YE6S plates or
YE6S plates containing 2.5- or 5.0-mM HU. The plates were incubated for 3 days at 30°C and
then photographed.
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DISCUSSION
In this study, we show that a single missense mutation in erg12 gene that replaces
residue Alanine142 with threonine in mevalonate kinase (MVK in human), an essential
enzyme required for mevalonate and ergosterol biosynthesis in all eukaryotes (Figures 4
and 14). The erg12 mutation significantly sensitizes S. pombe to chronic treatment of
HU. The mutated alanine residue is highly conserved in all examined eukaryotic enzymes
(Figure 15), suggesting that it is an important residue for catalysis or protein structure of
the enzyme. However, the exact mechanism of the HU-mediated cytotoxicity remains
unknown. Since our previously identified erg11-1 mutant is killed by HU via cytokinesis
arrest, it is possible that the HU-induced lethality of this erg12 mutant is caused by
cytokinesis arrest, not DNA replication arrest. The mutation in mevalonate kinase may
lead to sterol deficiency as in erg11-1 that might be the reason of cytokinesis arrest by
HU [25,26,34].
Mevalonate kinase converts mevalonate (mevalonic acid) to mevalonate
phosphate in the mevalonate pathway. Although this enzymatic step in the mevalonate
pathway is not rate-limiting, it is controlled by the feedback inhibition by
geranylpyrophosphate, farnesylpyrophosphate (FPP), and geranylgeranylpyrophosphate
(GGPP) (Figure 4) [19]. The mevalonate pathway provides the precursor of various
important biochemical products like prenylated proteins, heme A, dolichol, ubiquinone10, isopentenyl tRNAs and cholesterols (Figure 5B) [9,29,12,31]. Inhibition of
mevalonate kinase may reduce the production of these end products and thereby affect
diverse cellular processes. Mutations in erg12 may reduce the enzymatic activity of
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mevalonate kinase and thus sensitizes the cells to the stress induced by HU. In humans,
mutations in MVK gene cause accumulation of mevalonic acid in body tissues and fluids
leading to mevalonic aciduria (MVA). Another mild form of mevalonic aciduria is hyperimmunoglobulinemia D and periodic fever syndrome (HIDS) which is characterize by
high levels of immunoglobulin D (IgD). The level of mevalonic acid in HIDS patients is
much lower than in classic mevalonic aciduria and occurs only during episodes of fever
[9,12]. HIDS and MVA are rare autosomal recessive inherited disorders due to the
mutations in MVK causing deficiency in MVK enzyme [9,12,31]. Not all MVK mutations
have the same effect on the enzyme and not all metabolites are affected equally, which
leads to a broad spectrum of clinical forms of mevalonic aciduria. Literature reported that
the mutation at A148T in MVK (A142T in Erg12) is responsible for HIDS phenotype
[12]. The alanine residue resides in the ATP binding site of the enzyme. Threonine
substitution of this alanine likely affects ATP binding and thus kinase activity [12]. More
studies are needed to investigate the effect of this mutation on the activities of other
metabolite kinases or on ATP binding activity.
MVA is a fatal multi-systemic disease. Its clinical manifestations begin in infancy
or in early age, that include psychomotor retardation, failure to thrive,
hepatosplenomegaly, anemia, progressive cerebellar ataxia, dysmorphic features,
progressive visual impairment (cataract) and recurrent febrile episodes [12,31]. HIDS is
milder than MVA condition, only febrile attacks are present concomitant with
lymphadenopathy, arthralgia, gastrointestinal problems and skin rash. It is not fully
understood how the inflammatory periodic fever syndrome is related to the reduced
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activity of MVK. However, the increases of IgD levels are possibly stimulating the
immune system leading to inflammatory periodic fever syndrome [12,31].
As mentioned above, deficient activity of the MVK enzyme affecting the
production of the isoprenoids leading to shortage of FPP and GGPP and hence reduced
protein prenylation. Reduced protein prenylation may cause cluttered overactivation of
the small GTPases (Ras superfamily), which activate the production of the proinflammatory cytokines like IL-1β, IL-6, IL-18 and TNF (tumor necrosis factor) [12,31].
The protein prenylation process influences the functions of many proteins and regulate
the protein- protein binding with the help of the small GTPases (the Ras super family)
[8,31]. Disruption of protein prenylation leads to dysfunctional proteins [8,17,19].
Interestingly, in this study, two of these Ras family genes were found while studying the
HU mutant: mug109 encoding Rab GTPase binding protein and hba1 encoding Ran
GTPase binding protein (Figures 13B,13C). These Ras family genes are identified as
multiple-copy suppressors of erg12 since they are not mutated in the mutant and their
overexpression rescue the erg12 mutant (Figure 21). The identified genetic interactions
among the protein prenylation, Ras family genes, mevalonate pathway and the ergosterol
pathway may provide explanations for drug resistance or new therapeutic opportunities
for antifungal or anticancer therapies. For example, previous studies have shown that
applying the prenylation inhibitors in inhaler with the standard therapy of non-small cell
lung cancer may improve the therapeutic outcome [19]. Furthermore, prenylation
inhibitors have antiviral activity and could help in hepatitis cases [8].
So far, there is no FDA-approved treatment for MVK deficiency (MKD) or HIDS
yet [9,12]. But the inflammation and the other symptoms can be reduced to a certain
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extent. Patients use paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs)
during febrile inflammatory attacks, or moving to corticosteroids (prednisolone),
proceeding to cytokine blockade like IL-1 receptor antagonist (Anakinra). If failure
occurs, then use anti-TNF agents. In most severely affected patients, stem cell
transplantation must be done [9,12]. The results from this study may promote the
therapeutic innovations for the benefits of patients with HIDS.
The FPP is also considered as a precursor for the biosynthesis of the dolichol
chains, which is a cofactor in protein glycosylation, a process initiated in the endoplasmic
reticulum (ER) and called dolichol-dependent glycosylation that ends with the formation
of DolPP-oligosaccharide [1,31]. 𝛼1,2-mannosidase enzyme (Mns1) (MAN1B1 in
human) is an enzyme responsible for protein deglycosylation involved in glycoprotein
catabolic process and in the cell wall oligosaccharides formation [1]. The 𝛼-glucosidases
and 𝛼-mannosidases are responsible for trimming the glycoprotein Glc3Man9GlcNAc2
by removing three glucose and one mannose residues to form smaller oligosaccharide
Man8GlcNAc2 for further processing and maturation [14,30]. These glycosylation
reactions are well conserved in the higher eukaryotic organisms. The mns1 gene was
found in our screening as a multiple-copy suppressor for erg12 mutation. The plasmids
that contained mns1 gene partially rescued the erg12 mutant as well as the previously
identified erg mutants erg7 and erg25 (Figure 21 and 22), indicating that up-regulation of
Mns1 enzyme may play a role in the perturbed mevalonate or ergosterol pathway. The
inhibitor of 𝛼1,2-mannosidase could block the abnormal oligosaccharides formation,
leading to reduce the metastasis and tumor growth [14,30]. Inhibitors of this enzyme may
help in designing novel therapeutic agents that prevent misfolded proteins degradation in
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some genetic diseases that are characterized by rapid degradation of misfolded
glycoproteins. Kifunensine is one of the known inhibitors 𝑜𝑓 𝛼1,2-mannosidase [30].
Chitin synthase enzyme Chs1 (not represented in humans) is another enzyme that
functions in cell wall oligosaccharides formation and is involved in protein glycosylation
process. This enzyme converts UDP-N-acetylglucosamin (UDP-GlcNAc ) to chitin. The
chitin then connects to 𝛽-1,3-glucan and 𝛽-1,6-glucan which in turn link to mannan to
form higher polysaccharides cell wall [18,22]. The chs1 gene was found in our screening
as a suppressor for erg mutants. The plasmids that contained chs1 gene did not rescue the
erg12 mutant (Figure 21) but rescue erg7 and erg25 (Figure 22), indicating that Chs1
must play a role in the ergosterol pathway. Targeting chitin synthase is a new approach
that is under clinical trial to develop new and safe antifungal agents such as nikkomycin
[18].
In addition, UDP-glucose 4-epimerase enzyme Uge1 (GALE in human) involved
in galactosylation of glycoproteins in S. pombe in Leloir pathway (Figure 7). The enzyme
converts β-D-galactose to glucose-1-phosphate in S. pombe [28,32]. uge1 was found in
our screening as a multiple-copy suppressor for ergosterol mutations. The plasmids that
contain uge1 gene rescued the erg12 mutant (Figure 21) as well as the previously
identified erg mutants erg7 and erg25 (Figure 22), indicating the genetic connection of
Uge1 enzyme to the ergosterol pathway. Inhibitor of glucan synthase is a new class of
antifungal agents such as caspofungin [6].

55

CONCLUSION
In this study, we have identified a missense mutation in erg12 encoding mevalonate
kinase that is required for mevalonate and ergosterol biosynthesis (Figure14). Consistent
with our previously identified mutations in erg11-1, erg7-1, and erg25-1, this mutation
likely perturbs the ergosterol biosynthesis and thereby sensitizing the cells to HU by
cytokinesis arrest or other mechanisms. This result is consistent with our hypothesis of an
alternative cell-killing mechanism of HU. The mevalonate pathway has an essential role
in cell growth regulation. It is therefore a potential target for anti-cancer chemotherapy
[13,20]. Studies have shown that combination therapy of the two classes of MVK
inhibitors statin and bisphosphonate can extend the lifespan of some cancer patients
[19,29]. The suppressor genes that we have found in this study might shed new light on
the incompletely understood cell-killing mechanisms of HU. Further characterization for
these suppressor genes may provide new therapeutic targets or promote the development
of new combination therapies to overcome drug resistance or improve the therapeutic
efficacy for the benefit of the patients with cancers or fungal infections.
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